Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
Saeed K, Ojamies P, Pellinen T, Eldfors S, Turkki R, Lundin J, Järvinen P, Nisen H, Taari K, Af Hällström TM, Rannikko A, Mirtti T, Kallioniemi O, Östling P. Saeed K, et al. Among authors: jarvinen p. Int J Cancer. 2019 Mar 15;144(6):1356-1366. doi: 10.1002/ijc.31815. Epub 2018 Nov 4. Int J Cancer. 2019. PMID: 30125350 Free article.
Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy.
Eineluoto JT, Sandeman K, Pohjonen J, Sopyllo K, Nordling S, Stürenberg C, Malén A, Kilpeläinen TP, Santti H, Petas A, Matikainen M, Pellinen T, Järvinen P, Kenttämies A, Rannikko A, Mirtti T. Eineluoto JT, et al. Among authors: jarvinen p. Eur Urol Focus. 2021 Nov;7(6):1316-1323. doi: 10.1016/j.euf.2020.06.016. Epub 2020 Jun 30. Eur Urol Focus. 2021. PMID: 32620540
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F, Ylösmäki E, Chiaro J, Giannoula Y, Long M, Fusciello M, Feola S, Martins B, Feodoroff M, Antignani G, Russo S, Kari O, Lee M, Järvinen P, Nisen H, Kreutzman A, Leusen J, Mustjoki S, McWilliams TG, Grönholm M, Cerullo V. Hamdan F, et al. Among authors: jarvinen p. J Immunother Cancer. 2021 Aug;9(8):e003000. doi: 10.1136/jitc-2021-003000. J Immunother Cancer. 2021. PMID: 34362830 Free PMC article.
T and NK cell abundance defines two distinct subgroups of renal cell carcinoma.
Lee MH, Järvinen P, Nísen H, Brück O, Ilander M, Uski I, Theodoropoulos J, Kankainen M, Mirtti T, Mustjoki S, Kreutzman A. Lee MH, et al. Among authors: jarvinen p. Oncoimmunology. 2022 Jan 4;11(1):1993042. doi: 10.1080/2162402X.2021.1993042. eCollection 2022. Oncoimmunology. 2022. PMID: 35003893 Free PMC article.
Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH, Theodoropoulos J, Huuhtanen J, Bhattacharya D, Järvinen P, Tornberg S, Nísen H, Mirtti T, Uski I, Kumari A, Peltonen K, Draghi A, Donia M, Kreutzman A, Mustjoki S. Lee MH, et al. Among authors: jarvinen p. Cancer Res Commun. 2023 Jul 18;3(7):1260-1276. doi: 10.1158/2767-9764.CRC-22-0514. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37484198 Free PMC article.
285 results